Core Insights - NANO Nuclear Energy Inc. has signed a feasibility study agreement with BaRupOn LLC to evaluate the deployment of multiple KRONOS MMR units to generate 1 GW of nuclear energy at BaRupOn's Liberty American Multi-Sourced Power and Innovation Hub in Texas [2][3][4] Company Overview - NANO Nuclear is focused on developing advanced nuclear micro modular reactors and clean energy solutions, positioning itself as a key player in the nuclear energy sector [2][16] - The company aims to become a commercially focused, diversified, and vertically integrated entity across various business lines, including microreactor technologies and nuclear fuel fabrication [16][17] Project Details - The feasibility study will assess the projected power demand, reactor integration requirements, and site suitability for deploying KRONOS MMR units at the LAMP property [3][4] - BaRupOn anticipates that the deployment of KRONOS MMR units will enhance U.S. industrial capacity and energy resilience, particularly for high-density data processing [6][9] Industry Context - There is a significant and accelerating power demand in Texas and across the U.S., driven by the tech industry's need for high-performance computing and digital processing [4][7] - The collaboration with BaRupOn is seen as a strategic opportunity for NANO Nuclear to address the growing energy needs of AI and data center projects [5][9] Technological Aspects - The KRONOS MMR is a high-temperature, gas-cooled microreactor designed for modular deployment and scalable output, capable of powering large industrial campuses [7][10] - NANO Nuclear's microreactors are positioned as a solution to the limitations of traditional grid infrastructure, providing reliable, emission-free power [6][9]

Core Insights - ONGold Resources Ltd. has expanded its claims around the Ti-pa-haa-kaa-ning (TPK) project by staking an additional 73 claims, increasing the total area to approximately 69,764 hectares, which represents a 46% increase in the claim area [1][4] Group 1: Acquisition and Claims Expansion - The newly staked claims cover approximately 21,969 hectares (1,118 cells) and are aimed at exploring extensions of the Mameigwess and Bartman Lake Greenstone Belts and the Stull-Wunnumin Fault Zone [1] - The TPK property now consists of 2,504 claims, enhancing ONGold's exploration potential for gold and base metals deposits [1] Group 2: Exploration Activities - A recent diamond drilling program at the Gold Ridge area of TPK has indicated the presence of a large, intrusive-hosted, orogenic gold system, although no mineral resource has been defined yet [2] - Historical drilling at the Big Dam area has revealed significant gold intersections, including 25.9 g/t Au over 13.5 meters and other high-grade results [3] Group 3: Future Plans and Agreements - The company has entered into a Memorandum of Understanding (MOU) with the Chapleau Cree First Nation regarding support for exploration activities, which includes issuing 50,000 common shares and warrants [8] - The MOU outlines provisions for exploration conduct and negotiations for an impact benefit agreement (IBA) [8]

Core Insights - Parkit Enterprise Inc. has contributed 3.55 acres of land in London, Ontario, to a joint venture valued at $12,900,000 for residential redevelopment [1][2] - The joint venture consists of Parkit (50% share), Decade Capital (25% share), and Southside Group (25% share) [1][2] - Construction of two 15-story rental buildings, totaling 543 units, is set to begin in Q4 2025 [1][3][4] Contribution Details - The property contribution is valued at $12,900,000, and Parkit utilized a tax-free rollover to defer initial tax liabilities [2] - The joint venture aims to develop the site into a two-phase residential community [2] Residential Development Strategy - Parkit identified the highest and best use of the site as a transition from industrial to residential zoning [3] - The site is strategically located across from Fanshawe College, which has over 43,000 students, and along a new rapid-transit corridor [3] - The redevelopment plan includes two 15-story buildings with a total gross floor area of 487,151 square feet [3] Approval and Construction Timeline - The joint venture has received municipal approval and building permits for the first building, which will have 250 units and a gross floor area of 234,071 square feet [4] - Construction is scheduled to commence in Q4 2025, aligning with Parkit's strategy to unlock value through repositioning underutilized assets [4] Partner Profiles - Decade Capital is a real estate investment and development firm focused on high-potential assets, known for its strategic vision and execution [5] - Southside Group is a diversified real estate development and property management company with a strong legacy in Southwestern Ontario [6] Company Overview - Parkit Enterprise is focused on acquiring, growing, and managing strategically located industrial properties in key urban markets across Canada [7]

Core Insights - Riley Gold Corp. has provided an exploration update for its Pipeline West/Clipper Gold Project (PWC) in the Cortez mining district, operated by Kinross Gold U.S.A., Inc. under an earn-in agreement [3][4] - The 2025 drilling results have confirmed the presence of Carlin-type gold mineralization, indicating a potential for significant gold deposits in the area [5][7] - Kinross has expanded the PWC property size to 27.2 square kilometers and is planning further exploration activities for 2026 [4][7] Exploration Program - Kinross is planning a committed next phase of exploration at PWC, which will include additional framework drilling in 2026 based on previous drill results [4] - A geochemical soil survey is currently underway to delineate a +3km open gold and pathfinder element soil anomaly [4] - The geological model for PWC is being updated to compare with other significant gold discoveries in the Cortez District [4] Drilling Results - The 2025 drilling program has highlighted significant intersections, including up to 2.19 g/t gold and a notable 489ft (149m) thick intersection of disseminated gold mineralization [7][16] - Drill holes PW25-02 and PW25-03 have confirmed the presence of Carlin-type fluid signatures, indicating a possible Carlin-type gold system within the PWC claim block [11][24] - The results show evidence of hydrothermal fluid leakage along high-angle faults, consistent with geological settings observed in nearby significant deposits [5][13] Geological Context - The PWC project is situated along the Cortez structural zone, known for its productive gold deposits, with the potential for Carlin-type, disseminated, and replacement gold deposits [29] - The geological setting is analogous to the Meikle Mine and Barrick's Fourmile Project, which are known for their substantial gold reserves [4][5] Company Outlook - The CEO of Riley Gold expressed confidence in the exploration potential, noting that early drilling results are promising and could lead to significant discoveries similar to the Fourmile deposit [28] - The company is focused on maximizing shareholder value through exploration and development in the gold-rich Cortez Trend [32]

Core Viewpoint - First Phosphate Corp. has successfully closed a subsequent tranche of its non-brokered private placement financing, raising significant funds to support its operations and growth strategy [1][2]. Financing Details - The company raised gross proceeds of $3,570,848 through the issuance of 3,355,832 Flow-Through Shares and 611,777 Hard Dollar Units [2]. - In the latest tranche, the company raised $1,390,699, which includes $999,999 from 1,111,110 Flow-Through Shares and $390,700 from 431,111 Hard Dollar Units [2][3]. - To date, First Phosphate has raised approximately $43.6 million through 10 management-led non-brokered private-placement financings since June 2022 [3]. Compensation and Incentives - The company granted 4,700,000 incentive stock options and 1,303,000 restricted stock units as part of its compensation plan [5]. - Each option has an exercise price of $0.90 and will vest over two years, while the RSUs will vest on January 1, 2026 [5]. Company Overview - First Phosphate is focused on developing a vertically integrated lithium iron phosphate battery supply chain for North America, targeting markets such as energy storage and national security [6]. - The company's flagship property, Bégin-Lamarche, is noted for its high-purity phosphate resources [7].

Core Viewpoint - NervGen Pharma continues to demonstrate significant progress in the development of NVG-291, a potential first-in-class treatment for spinal cord injury, with promising clinical data supporting its efficacy in restoring function and improving quality of life for patients [3][4][6]. Pipeline Progress - The expanded CONNECT SCI Study data shows that NVG-291 leads to durable improvements in function, independence, and quality of life, with participants reporting a 2.6-fold greater mean improvement in GRASSP Total Score and a 3.7-fold greater mean improvement in GRASSP Quantitative Prehension compared to placebo [4][6]. - The FDA confirmed multiple regulatory pathways for NVG-291's approval, highlighting the significant unmet medical need for spinal cord injury treatments [6][8]. Financial Progress - On November 19, 2025, the company completed a non-brokered private placement, raising approximately US$10 million, which will support its anticipated Nasdaq listing [9]. - As of September 30, 2025, NervGen had cash and investments totaling US$11.4 million, a decrease from US$17.3 million at the end of 2024, primarily due to operational activities related to the CONNECT SCI Study [10]. Corporate Progress - In July 2025, the company appointed Adam Rogers, MD, as Interim Chief Executive Officer and Randall Kaye, MD, as Chief Medical Advisor to strengthen its leadership for the late-stage development of NVG-291 [10][12]. - The company is focused on advancing NVG-291 in collaboration with the spinal cord injury community and the FDA [3][8]. Research & Development Expenses - R&D expenses for the three months ended September 30, 2025, were US$4.4 million, consistent with the same period in 2024, reflecting higher costs for drug supply procurement and regulatory requirements [11]. General and Administrative Expenses - G&A expenses decreased to US$1.7 million for the three months ended September 30, 2025, from US$2.8 million in the same period in 2024, due to reduced non-cash stock-based compensation and lower legal and professional expenses [14]. Net Loss - The net loss for the three months ended September 30, 2025, was US$4.2 million, or US$0.06 per share, an improvement from a net loss of US$5.3 million, or US$0.08 per share, in the same period in 2024 [15]. About NVG-291 - NVG-291 is a therapeutic peptide that enables the nervous system to repair itself, with exclusive worldwide rights held by NervGen. The technology is based on studies showing its efficacy in promoting neurorepair and functional improvement in spinal cord injury models [16]. About NervGen - NervGen Pharma is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurotrauma and neurologic diseases, with its lead candidate NVG-291 currently in the Phase 1b/2a CONNECT SCI Study [17].

Core Insights - iHuman Inc. will present at NobleCon21 on December 3rd, 2025, showcasing its tech-powered intellectual development products aimed at enhancing child upbringing experiences for parents and children [1][2]. Company Overview - iHuman Inc. is a leading provider of tech-powered intellectual development products in China, focusing on making child upbringing easier for parents and transforming intellectual development into an enjoyable journey for children [3]. - The company has nearly three decades of experience in the parenthood industry, combining superior original content, advanced technology, and research capabilities to empower parents [3]. - iHuman offers a comprehensive suite of innovative products, including self-directed apps, interactive content, and smart devices, aimed at developing children's abilities in speaking, critical thinking, independent reading, and creativity [3]. - The company leverages advanced technologies such as 3D engines, AI/AR functionality, and big data analysis to enhance the experience for both parents and children [3]. Event Details - Interested investors can attend the presentation at a discounted rate using the code [IHNOBLECON], and a high-definition video webcast will be available the following day on Noble Capital Markets' website and Channelchek [2].

Company Leadership Changes - Pure Energy Minerals Limited has appointed Mr. William Morton as President and Chief Executive Officer, effective immediately, bringing over 30 years of executive leadership experience in private equity and clean energy infrastructure [1][2] - Mr. Joseph Mullin has resigned from his position as President and CEO as well as from the Board of Directors to pursue a new opportunity, with the Board expressing gratitude for his leadership during a challenging lithium industry market [2] Incentive Share Purchase Options - The Board of Directors has granted Mr. Morton 364,228 incentive share purchase options, allowing him to acquire common shares at an exercise price of $0.30 per share until November 20, 2030 [2] - Following this grant, the total number of options granted by the Company is now 2,794,500, representing 8% of the Company's outstanding shares [2] Company Overview - Pure Energy Minerals is focused on lithium resource development, particularly at its Clayton Valley Project in Nevada, where it has consolidated land for exploration and development [3] - The Company has an Earn-In Agreement with Schlumberger Technology Corp., allowing Schlumberger to acquire all of the Company's interests in the Clayton Valley Project [3]

Core Insights - NervGen Pharma announced expanded data from the CONNECT SCI Study, showing significant and durable improvements in function, independence, and quality of life for individuals with chronic spinal cord injury (SCI) [2][3][14] Study Overview - The CONNECT SCI Study was a 16-week placebo-controlled trial involving 20 participants with an average of 3.5 years post-injury, who received either NVG-291 or a placebo [5] - Participants were randomized to receive daily subcutaneous NVG-291 for 12 weeks, followed by a 4-week observation period to assess the durability of the response [5] Clinical Efficacy - NVG-291 demonstrated a 2.6-fold greater mean improvement in the GRASSP Total Score compared to placebo at Week 16 [11] - Hand function improvements were 3.7-fold greater in NVG-291 participants compared to placebo at Week 16 [11] - 75% of NVG-291 participants reported "much" or "very much" improved overall symptoms compared to 33% on placebo [11] - 67% of NVG-291 participants reported improved bladder control compared to 22% of placebo participants [11] - 56% of NVG-291 participants reported reduced muscle spasticity compared to 22% of placebo participants [11] Biological Mechanism - NVG-291 treatment resulted in a statistically significant reduction of hyperactive reticulospinal signaling in both upper and lower limbs, establishing a biological basis for its clinical efficacy [10][18] - The treatment also correlated with strengthened corticospinal signaling, indicating restored balance between voluntary and involuntary motor pathways [18] Quality of Life Improvements - Blinded exit interviews highlighted real-world impacts, with participants reporting enhanced daily activities and independence post-treatment [9][8] - Participants noted improvements in bladder control and reduced muscle spasticity, contributing to a better quality of life [9][11] Regulatory Progress - The company completed a Type C meeting with the FDA, confirming multiple regulatory pathways available for NVG-291's approval due to the significant unmet medical need in SCI [15][19] - NervGen has received Fast Track designation from the FDA and Orphan Designation from the EMA for NVG-291 [19] Future Directions - The company anticipates an End-of-Phase 2 meeting in early 2026 to align with the FDA on the development and registration pathway for NVG-291 [15]

Core Points - Nutriband Inc. will have its Chairman and Co-Founder, Serguei Melnik, present at NobleCon21 on December 3rd, 2025, at 9:30 AM Eastern Standard Time [1] - Interested investors can attend the conference at a discounted rate using the code NTRBNOBLECON [2] - A high-definition video webcast of the presentation will be available the following day and archived for 90 days [3] Company Overview - Nutriband Inc. focuses on developing transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch utilizing AVERSA™ technology [4] - AVERSA™ technology aims to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential [4] Noble Capital Markets - Noble Capital Markets, established in 1984, is a full-service broker-dealer providing investment and advisory services, with a strong research team and a proprietary research distribution platform [6] - Noble has raised billions of dollars for companies and published over 45,000 equity research reports [6] Channelchek - Channelchek, launched in 2018, is an investor community dedicated to emerging growth public companies, offering free institutional-quality research and advanced market data [7]